JNJ vs BMY
By Alex · Tickerpine
Johnson & Johnson vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | BMY |
|---|---|---|
| Price | $260.86 | $63.70 |
| Market cap | $628.65B | $130.12B |
| P/E ratio | 30.3 | 14.0 |
| ROE | 25.74% | 46.60% |
| Profit margin | 21.48% | 18.87% |
| Revenue growth | 6.60% | 5.70% |
| Dividend yield | 2.05% | 3.96% |
| Beta | 0.23 | 0.23 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs BMY in plain English
- JNJ is the bigger company — about 4.8× the market cap of BMY.
- BMY is cheaper on earnings (P/E 14.0 vs 30.3).
- BMY earns a higher return on equity (47% vs 26%).
- JNJ is growing revenue faster (7% vs 6%).
- BMY has the higher dividend yield (3.96% vs 2.05%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.